A recent article in The Wall Street Journal argues that Anthem’s lack of participation in recent healthcare deals puts it in a strong position for the future. The article cites lengthy regulatory reviews standing in the way of deals such as Walmart and Humana, CVS and Aetna, as well as unpopularity among stakeholders. While other companies are entering uncharted territory, Anthem can wait and see how the abundance of deals progresses.

Full story from The Wall Street Journal‘s Charley Grant here.